

JC10 Rec'd PCT/PTO 01 JUN 2005

Attorney Docket No. 441071/PALL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SAMUEL SOWEMIMO-COKER

Application No. 10/532209

Filed: April 22, 2005

For: BIOLOGICAL FLUID FILTER

Group Art Unit: 1797

Examiner: Unassigned Marjorie

__Marjorie Christian

ž.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as

In re Appln. of SAMUEL SOWEMIMO-COKER Application No. 10/532209

	set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	or the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.
Copie	s of the References
	Copies of the references listed on the enclosed Form 1449 are enclosed herewith.
×	Copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith. Copies of other references identified on the accompanying Form 1449 are enclosed herewith.
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
\boxtimes	A copy of the foreign search report is enclosed herewith.
	The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not

In re Appln. of SAMUEL SOWEMIMO-COKER

Application No. 10/532209

submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLI	CATIONS	Status (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
1.					
2.					
3.					

Statement under 37 CFR 1.97(e) The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement. The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement. Statement under 37 CFR 1.704(d) The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. Fees No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Attached is a check in the amount of \$		
Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement. The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement. Statement under 37 CFR 1.704(d) The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(e) more than thirty days prior to the filing of the Information Disclosure Statement. Fees No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Attached is a check in the amount of \$. (A duplicate copy of Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of	Staten	nent under 37 CFR 1.97(e)
Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement. Statement under 37 CFR 1.704(d) The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filling of the Information Disclosure Statement. Fees No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Attached is a check in the amount of \$ (A duplicate copy of the Charge Deposit Account No. 12-1216 in the amount of \$ (A duplicate copy of the content of the country of the amount of \$ (A duplicate copy of the country of the country of the amount of \$ (A duplicate copy of the country of the country of the amount of \$ (A duplicate copy of the country of the country of the amount of \$ (A duplicate copy of the country of the country of the country of the amount of \$ (A duplicate copy of the country of the count		Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three
The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. Fees No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$ (A duplicate copy of		Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information
Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filling of the Information Disclosure Statement. Fees No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$ (A duplicate copy of	Staten	nent under 37 CFR 1.704(d)
No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$ (A duplicate copy of		Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing
The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$ (A duplicate copy of	Fees	
Attached is a check in the amount of \$ Charge Deposit Account No. 12-1216 in the amount of \$ (A duplicate copy of	\boxtimes	
Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of	Metho	od of Payment of Fees
		Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of

In re Appln. of SAMUEL SOWEMIMO-COKER

Application No. 10/532209

Authorization to Charge Additional Fees

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

Instructions as to Overpayment

Credit Account No. 12-1216.
Refund

Respectfully submitted,


Jeremy M. Vay, Reg. No. 33,3 LEYDIS, VOIT & MAYER

700 Thirteenth Street, N.W., Suite 300 Washington, DC 20005-3960

(202) 737-6770 (telephone) (202) 737-6776 (facsimile)

Date: 1 June 2005

IDS (Revised 1/14/05)



BADEMAR

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 1 of

<i>y</i>	•
7	Complete if Known
Application Number	10/532,209
Filing Date	April 22, 2005
First Named Inventor	Samuel Sowemimo-Coker
Group Art Unit	1797
Examiner Name	Unassigned Marjorie Christian

441071/PALL

		U.C. Datest Day		S. PATENT DOCUMENTS	T	
Examiner Initials	Doc. No.	U.S. Patent Document Application or Kind Patent Number Code		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	B1	3,668,925		Mesek	6/13/1972	
/M.C./	B 2	4,701,267		Watanabe et al.	10/20/1987	
					-	

Attomey Docket Number

				FOREIGN	PATENT DOCUMENTS					
		Foreign Patent Document		Foreign Patent Document		nt			Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+		
				-						
				+				-		
							<u> </u>	 		

	OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item					
		(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+			
M.C./	В3	Sowemimo-Coker, S. O., et al., Transfusion 42:9S, 60S 2002 (Abstract SP110)					

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

/Mariorie Christian/

Examiner Signature

Date Considered

01/26/2009

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).